location:home -> CONTRACT RESEARCH ON PT
CONTRACT RESEARCH ON PEPTIDE THERAPEUTICS http://www.acinopeptide.com
The total market for peptides therapeutics in 2011 was approximately US$100 billion, and is growing in excess of 15% pa. Although peptides are excellent drug leads the instability of these molecules in the human body limits their therapeutic value and pharmaceutical use. Despite of this limitation peptide drugs currently represent a small but growing number of pharmaceutical molecules. The interest in peptide drugs has recently intensified with key developments in the following areas:
- Modifications of peptides with non-natural amino acids to increase stability.
- Improvements in manufacturing to increase yield and reduce cost.
- Synthesis of diverse peptide libraries to screen large sets of drug targets.
- Development of phage display technology to identify target specific peptides.
Peptides are currently being developed for therapeutic applications in a variety of clinical indications. Some of these indications are: allergy/asthma; arthritis; cancer; diabetes; growth impairment; cardiovascular diseases; inflammation; vaccines; baldness; analgesia; ophthalmology; epilepsy; gynecology; CNS diseases; antiviral; antibacterial; GI diseases; obesity; and hemostasis.
An analysis of launched peptide drugs and compounds in late stage development indicates that the peptide market is expected to grow in 2012 at a rate of 5%. Beginning in late 2012, however, Phase III and some Phase II candidates will start moving through the registration approval process. As these drugs gain approval and are marketed, the overall peptide market is expected to grow at a rate of 10% with growth rates increasing toward the end of this decade and beyond.
Considering the growing market in peptide therapeutics contract research, there is dramatic improvement in regulatory scenario to accommodate this change. CRO industry has rewritten the rules in drug development area in
For the fulfillment of such requirement all the scientific academia or commercial houses have their eye on